81528-65-6

Basic information

• Product Name: N-(3-METHYLPYRIDIN-2-YL)ETHANE-1,2-DIAMINE
• Synonyms: N-(3-METHYLPYRIDIN-2-YL)ETHANE-1,2-DIAMINE;N-(3-methylpyridin-2-yl)ethane-1,2-diamine(SALTDATA: FREE)
• CAS NO: 81528-65-6
• Molecular Formula: C8H13N3
• Molecular Weight: 151.21
• Mol File: 81528-65-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 309.2°C at 760 mmHg
• Flash Point: 140.8°C
• Appearance: /
• Density: 1.091g/cm³
• Vapor Pressure: 0.00065mmHg at 25°C
• Refractive Index: 1.592
• CAS DataBase Reference: N-(3-METHYLPYRIDIN-2-YL)ETHANE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-METHYLPYRIDIN-2-YL)ETHANE-1,2-DIAMINE(81528-65-6)
• EPA Substance Registry System: N-(3-METHYLPYRIDIN-2-YL)ETHANE-1,2-DIAMINE(81528-65-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 81528-65-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H13N3/c1-7-3-2-5-10-8(7)11-6-4-9/h2-3,5H,4,6,9H2,1H3,(H,10,11)

Upstream product

• 18368-76-8 2 chloro-3-methylpyridine 
• 107-15-3 ethylenediamine 

Relevant articles and documents

Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA

A method is described for the NMR-based screening for the discovery of aminoglycoside mimetics that bind to Escherichia coli A-site RNA. Although aminoglycosides are clinically useful, they exhibit high nephrotoxicity and ototoxicity, and their overuse ha

Cardioactive aryloxypropanolamines

The present invention provides aryloxypropanolamines of the general formula: STR1 wherein R1, R2, R3 and R4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamido, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R5 and R6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R1, R2, R3 and R4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R7, R8, R9, R10 and R11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, nitro, hydroxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-(lower alkoxycarbonyl)-ethyl, 2-carboxyethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.